Nitrogen Attached Indirectly To The Six-membered Hetero Ring By Nonionic Bonding Patents (Class 514/357)
  • Patent number: 11905231
    Abstract: The present disclosure relates to solid forms and salts, crystalline and otherwise, of (E)-2-[[3-(3-methoxy-4-propargyloxy)phenyl)-1-oxo-2-propenyl]amino]benzoic acid and pharmaceutical compositions comprising same. The use of such solid forms, salts, and pharmaceutical compositions, for treating, preventing, or ameliorating diseases or conditions associated with fibrosis, inflammation and/or proliferation are disclosed.
    Type: Grant
    Filed: July 18, 2023
    Date of Patent: February 20, 2024
    Assignee: Certa Therapeutics Pty Ltd
    Inventors: Darren James Kelly, Gareth Rhys Lewis, Lorna Helen Mitchell
  • Patent number: 11883472
    Abstract: The present invention relates to rusalatide acetate compositions, formulations and dosage forms that include 23 amino acid monomer (“Monomer”), dimer (“Dimer”) of two 23 amino acid Monomers, or any combination of Monomer and Dimer, wherein any ratio, proportion or percentage of Monomer and Dimer may be present in the compositions, formulations and dosage forms. The invention also broadly covers stable compositions, formulations or dosage forms that include rusalatide acetate and any pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: August 27, 2020
    Date of Patent: January 30, 2024
    Assignee: AFFIRMED PHARMA, LLC
    Inventors: John K. Weatherspoon, Jane Lea Hicks
  • Patent number: 11839033
    Abstract: Disclosed are a method of directly patterning a stretchable substrate; and a stretchable electrode fabricated by the method. More particularly, the method of directly patterning a stretchable substrate includes: forming a hydrophilic group on a surface of a stretchable substrate by UV-ozone treatment; forming at least one layer to be etched on the hydrophilic group-formed stretchable substrate, wherein the at least one layer to be etched includes an adhesion enhancing material; forming a photoresist layer on the at least one layer to be etched; exposing the photoresist layer; and patterning the at least one layer to be etched using the exposed photoresist layer, wherein a carbon chain included in the adhesion enhancing material forms ether bonding (R—O—R) with a hydrophilic group formed on the surface of the stretchable substrate.
    Type: Grant
    Filed: April 25, 2022
    Date of Patent: December 5, 2023
    Assignee: KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION
    Inventors: Soong Ju Oh, Jun Sung Bang
  • Patent number: 11759640
    Abstract: Disclosed are methods to treat patients with AFib by monitoring their heart rhythm to determine the presence and/or the number of episodes of long duration AFib, and optionally the extent of AFib burden. Patients who meet threshold requirements are qualified for the treatment of AFib with a dosage of budiodarone. Patient monitoring is continued in order confirm that the patient is and remains responsive to budiodarone therapy including dose adjusting the patient to achieve such therapy. Subsequently, monitoring is continued to confirm that the patient remains responsive. These methods allow for treatment of the AFib and, correspondingly, reduce or delay the risk of stroke and/or congestive heart failure in the treated patient.
    Type: Grant
    Filed: November 1, 2022
    Date of Patent: September 19, 2023
    Assignee: Xyra, LLC
    Inventors: Pascal Druzgala, Peter Gerard Milner
  • Patent number: 11628164
    Abstract: Salsolinol is a metabolite of alcohol and is cytotoxic, so that the salsolinol has been studied as a diagnostic biomarker for a liver disease and a liver cancer, but the salsolinol has not been reported as a therapeutic agent for the liver disease or the liver cancer. Since the salsolinol regulates tumor-related genes and inflammation-related genes specifically for men, it is experimentally found that the salsolinol has an effect of alleviating a liver cancer and an alcoholic hepatitis. Therefore, the salsolinol is contained together with a pharmaceutically acceptable salt as an effective ingredient and is provided as a pharmaceutical composition for treating the liver cancer or a health functional food for preventing and improving the alcoholic liver disease to have an effect of treating the liver disease and the liver cancer or preventing and improving the liver disease and the liver cancer.
    Type: Grant
    Filed: November 6, 2020
    Date of Patent: April 18, 2023
    Assignee: Sungshin Women's University R&DB Foundation
    Inventors: Hye Kyung Na, Hong Kyung Yang, Hyun Jung Choi
  • Patent number: 11549198
    Abstract: The invention relates to non-woven protein fibers and to methods for forming and producing the same. In certain embodiments, the invention provides a method of processing a protein comprising dissolving a protein in a solution, optionally removing any insoluble materials from the solution, and spraying the solution under an applied pressure. In other embodiments, the protein can be derived from a range of sources, including but not limited to arthropod silks, animal keratin (e.g. hair and wool), tissue elastin, collagen, resilin, and plant protein. In certain embodiments, the methods of the invention are an alternative to electrospinning methods known in the art.
    Type: Grant
    Filed: April 17, 2018
    Date of Patent: January 10, 2023
    Assignee: Rowan University
    Inventors: Xiao Hu, Xiaoyang Mou
  • Patent number: 11548850
    Abstract: Compounds and methods for inhibiting cofilin activity or reducing total cofilin, improving motor deficits, attenuating LPS-induced microglial activation and inflammation, reducing microglial migration and proliferation, reducing TNF-?, reducing NF-?B, and improving motor deficits in a subject are described.
    Type: Grant
    Filed: May 5, 2020
    Date of Patent: January 10, 2023
    Assignee: The University of Toledo
    Inventors: Saleh Alaqel, Viranga Tillekeratne, Zahoor A. Shah
  • Patent number: 11524048
    Abstract: The present invention is related to the use of HMGB1 antagonists such as K883 in the treatment and/or prevention and/or inhibition of severe sepsis in mammals, e.g., humans, and pharmaceutical compositions for the same comprising HMGB1 antagonists in an effective amount to treat and/or prevent and/or inhibit this condition.
    Type: Grant
    Filed: May 8, 2020
    Date of Patent: December 13, 2022
    Assignee: THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH
    Inventor: Yousef Al-Abed
  • Patent number: 11510944
    Abstract: Methods for treating Wilson Disease with bis-choline tetrathiomolybdate therapy are provided. The methods may include administering 15 mg or between 30 and 90 mg of bis-choline tetrathiomolybdate once daily to a patient exhibiting NCC corrected, alamine aminotransferase (ALT), hemoglobin, platelets, or neutrophils levels meeting specified criteria. The methods may include modifying treatment by decreasing or increasing the daily dose of bis-choline tetrathiomolybdate or discontinuing treatment for a period of time.
    Type: Grant
    Filed: December 4, 2018
    Date of Patent: November 29, 2022
    Assignee: Alexion Pharmaceuticals, Inc.
    Inventors: Carl Bjartmar, Karl-Heinz Weiss, Michael Schilsky, Frederick Askari, Anna Czlonkowska, Peter Ferenci, Peter Hedera, Aftab Ala
  • Patent number: 11510942
    Abstract: The subject matter described herein is directed to stable L-cysteine compositions for injection, comprising: L-cysteine or a pharmaceutically acceptable salt thereof and/or hydrate thereof in an amount from about 10 mg/mL to about 100 mg/mL; Aluminum in an amount from about 1.0 parts per billion (ppb) to about 250 ppb; cysteine in an amount from about 0.01 wt % to about 2 wt % relative to L-cysteine; pyruvic acid in an amount from about 0.01 wt % to about 2 wt % relative to L-cysteine; a pharmaceutically acceptable carrier, comprising water; headspace O2 that is less than 1.0%; dissolved oxygen present in the carrier in an amount from about 0.01 parts per million (ppm) to about 1 ppm, wherein the composition is enclosed in a single-use container having a volume of from 10 mL to 100 mL. Also described are compositions for a total parenteral nutrition regimen and methods for their use.
    Type: Grant
    Filed: March 1, 2021
    Date of Patent: November 29, 2022
    Assignee: EXELA PHARMA SCIENCES, LLC
    Inventors: John Maloney, Aruna Koganti, Phanesh Koneru
  • Patent number: 11484513
    Abstract: The invention relates to a medicament, the active principle of which is Salbutamol. It can be applied to the prevention and/or treatment of eye diseases or disorders, especially of Ametropia (myopia, Presbyopia), hereditary dystrophies of the retina, glaucoma, cataract, Keratoconus, macular degeneration, diabetic retinopathy, orbital and ocular inflammation (optic neuritis, uveitis), vitreo retinal proliferation or fibrosis, conjunctivitis, dry eye and all the ophthalmic diseases or disorders including a decrease of visual function.
    Type: Grant
    Filed: June 27, 2017
    Date of Patent: November 1, 2022
    Inventor: Raouf Rekik
  • Patent number: 11472772
    Abstract: The present invention relates to antagonists of the S1P3 receptor formula (A) as herein described and pharmaceutical compositions thereof. The compounds of formula (A) are useful in the preparation of a medicament, in particular for the treatment of Alzheimer's disease.
    Type: Grant
    Filed: January 24, 2020
    Date of Patent: October 18, 2022
    Assignee: TEVA PHARMACEUTICAL INDUSTRIES LIMITED
    Inventors: Chiara Caramelli, Cesare Federico, Emanuele Gabellieri, Matteo Magnani, Iolanda Micco, Georg C. Terstappen
  • Patent number: 11426411
    Abstract: The invention is directed to a method of treatment for inflammation in mammals including inflammation caused by bacterial or viral infection, the method comprising administering to a mammal, including a human, in need of such treatment a therapeutically effective amount of a compound of formula I, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: August 19, 2020
    Date of Patent: August 30, 2022
    Assignee: MediSynergics, LLC
    Inventors: Dennis Michael Godek, Harry Ralph Howard, Andrew Morgan Stewart
  • Patent number: 11419832
    Abstract: Methods for treating Wilson Disease with bis-choline tetrathiomolybdate therapy are provided. The methods may include administering 15 mg or between 30 and 90 mg of bis-choline tetrathiomolybdate once daily to a patient exhibiting NCCcorrected, alanine aminotransferase (ALT), hemoglobin, platelets, or neutrophils levels meeting specified criteria. The methods may include modifying treatment by decreasing or increasing the daily dose of bis-choline tetrathiomolybdate or discontinuing treatment for a period of time.
    Type: Grant
    Filed: August 19, 2020
    Date of Patent: August 23, 2022
    Assignee: ALEXION PHARMACEUTICALS, INC.
    Inventors: Carl Bjartmar, Karl-Heinz Weiss, Michael Schilsky, Frederick Askari, Anna Czlonkowska, Peter Ferenci, Peter Hedera, Aftab Ala
  • Patent number: 11382901
    Abstract: An ophthalmic composition includes tropicamide, at least one cyclodextrin at concentrations of less than 2.5%, at least one surfactant at concentrations of less than 2.5%. The composition is physically stable at neutral pH.
    Type: Grant
    Filed: June 20, 2018
    Date of Patent: July 12, 2022
    Assignee: FOR HEALTH PHARMA S.R.L.
    Inventor: Sebastiano Mangiafico
  • Patent number: 11382900
    Abstract: Disclosed is a method for preventing or treating sleep disorders using TRPV1 receptor antagonist, (R)—N-[1-(3,5-difluoro-4-methanesulfonylamino-phenyl)-ethyl]-3-(2-propyl-6-trifluoromethyl-pyridin-3-yl)-acrylamide. The method of the present invention can effectively and safely prevent or treat sleep disorders accompanying pruritus caused by atopic dermatitis.
    Type: Grant
    Filed: February 28, 2020
    Date of Patent: July 12, 2022
    Assignee: AMOREPACIFIC CORPORATION
    Inventors: Gyeyoung Choi, Hyunjin Nam, Miyoung Park, Kyoungmi Jung, Jihae Lee, Chang Soon Choi, Youngho Park, Jong Hwa Roh, Eunsil Park, Jaehong Park, Kwanghyun Shin, Byoung Young Woo, Kiwha Lee, Wonkyung Cho, Joonho Choi
  • Patent number: 11241010
    Abstract: The present invention relates to the use of succinate dehydrogenase Inhibitors for extending shelf life and storage stability of fruits and vegetables, to a method for extending shelf life of fruits and vegetables by applying a succinate dehydrogenase inhibitor to the crops prior to the harvest of the fruits or vegetables and to a fruit or vegetable treated with a succinate dehydrogenase Inhibitor.
    Type: Grant
    Filed: December 18, 2019
    Date of Patent: February 8, 2022
    Assignee: Bayer Intellectual Property GmbH
    Inventors: Heiko Rieck, Helene Lachaise, Gilbert Labourdette, Peter Howard Davies, Dominique Steiger, Luk De Maeyer, George Hauley Musson, IV, Lorianne Fought, Sylvain Tafforeau
  • Patent number: 11168073
    Abstract: The present technology provides 3,3-difluoroallylamines or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and uses thereof. The 3,3-difluoroallylamines or their pharmaceutically acceptable salts exhibit potent inhibitory activity on VAP-1 and therefore can be usefully applied, e.g., for the treatment and prophylaxis of nonalcoholic hepatosteatosis (NASH).
    Type: Grant
    Filed: December 12, 2019
    Date of Patent: November 9, 2021
    Assignee: YUHAN CORPORATION
    Inventors: Tae Dong Han, Hee Jae Tak, Eun Kyung Kim, Eui Chul Lee, Sol Park, Hyok Jun Cho, Cheol Hee Lim, So Young Kim, Hyun Ho Choi, Da Na Jeong, Na Yeon Yang, Na Ry Ha
  • Patent number: 11147788
    Abstract: The present invention relates to compounds suitable for treating, ameliorating and/or preventing neuromuscular disorders, including the reversal of drug-induced neuromuscular blockade. The compounds as defined herein preferably inhibit the CIC-1 ion channel.
    Type: Grant
    Filed: December 14, 2017
    Date of Patent: October 19, 2021
    Assignee: NMD PHARMA A/S
    Inventors: Lars J. S. Knutsen, Thomas Holm Pedersen, Martin Broch-Lipps, Claus Elsborg Olesen, Marc Labelle, Ole Baekgaard Nielsen
  • Patent number: 11140903
    Abstract: Provided are methods for reducing the occurrence of sudden death syndrome in plants, such as soybeans, using compounds of the general formula (I).
    Type: Grant
    Filed: May 7, 2018
    Date of Patent: October 12, 2021
    Assignee: Bayer CropScience LP
    Inventors: Jennifer Riggs, David Doran
  • Patent number: 11116719
    Abstract: Methods of treating a human patient suffering from Eustachian tube malfunctions are provided. A nasal spray or pharmaceutical composition containing a therapeutically effective amount of betahistine is administered to the patient. The nasal spray or pharmaceutical composition has particular applicability to alleviate the symptoms of Meniere's disease in persons suffering from abnormal Eustachian tube function, but also has an applicability to beneficially improve vascular oxygenation of the inner ear.
    Type: Grant
    Filed: July 22, 2019
    Date of Patent: September 14, 2021
    Inventor: Burkhard Karl-Heinz Gunther Franz
  • Patent number: 11091479
    Abstract: The present technology provides triazolopyridin-3-ones or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and uses thereof. The triazolopyridin-3-ones or their pharmaceutically acceptable salts exhibit inhibitory activity on VAP-1 and therefore can be usefully applied, e.g., for the treatment and prophylaxis of nonalcoholic hepatosteatosis (NASH).
    Type: Grant
    Filed: December 12, 2019
    Date of Patent: August 17, 2021
    Assignee: YUHAN CORPORATION
    Inventors: Tae Dong Han, Hee Jae Tak, Eun Kyung Kim, Dong Hoon Kim, Su Bin Choi, Sol Park, Hyun Ho Choi, Tae Wang Kim, Mi Kyeong Ju, Na Ry Ha
  • Patent number: 11071724
    Abstract: Compositions for treating presbyopia may include active pharmaceutical ingredients of pilocarpine HCl, phenylephrine HCl, pheniramine maleate, and ketorolac tromethamine. Other ingredients may include boric acid, polyethylene glycol, propylene glycol, and BAK (benzalkonium chloride). The pilocarpine HCl may be in a range of 0.1% to 2%. The phenylephrine HCl may be in a range of 0.1% to 1.5%. The pheniramine maleate may be in a range of 0.07% to 0.35%. The ketorolac tromethamine may be in a range of 0.01% to 0.6%. The boric acid may be in a range of 0.5% to 1.5%. The polyethylene glycol may be in a range of 0.1% to 1%. The propylene glycol may be in a range of 0.1% to 1%. The BAK may be in a range of 0.005% to 0.01%. The solvent may be mostly water.
    Type: Grant
    Filed: October 2, 2019
    Date of Patent: July 27, 2021
    Assignee: OCULAR SCIENCE, INC.
    Inventors: Anthony Sampietro, Damien Goldberg, Amy Frost, Brian Holdorf
  • Patent number: 11059775
    Abstract: Prodrugs of hydroxamate-based GCPII inhibitors and methods of their use for treating a disease or condition are disclosed.
    Type: Grant
    Filed: November 20, 2017
    Date of Patent: July 13, 2021
    Assignees: The Johns Hopkins University, INSTITUTE OF ORGANIC CHEMISTRY & BIOCHEMISTRY
    Inventors: Barbara Slusher, Rana Rais, Jan Vavra, Tomas Tichy, Pavel Majer, Andrej Jancarik, Lukas Tenora
  • Patent number: 11040935
    Abstract: Described herein are compounds that disrupt the interaction between Fbxo48 and phosphorylated-AMPK.
    Type: Grant
    Filed: October 4, 2017
    Date of Patent: June 22, 2021
    Assignees: University of Pittsburgh—Of the Commonwealth System of Higher Education, The United States as represented by the Department of Veterans Affairs
    Inventors: Beibei Chen, Rama K. Mallampalli, Yuan Liu
  • Patent number: 11040949
    Abstract: Provided herein are compounds, derivatives thereof, composition comprising one or more of said compounds and derivatives, and methods for prevention and/or treatment of microbial infections and/or related diseases or conditions. The present compounds and/or derivatives thereof can be represented by Formula (II): The present methods include administering to a subject an effective amount of one or more compounds of Formula (II). In one embodiment, said microbial infections are bacterial infections. More specifically, said bacterial infections are staphylococcal infections.
    Type: Grant
    Filed: August 31, 2020
    Date of Patent: June 22, 2021
    Assignee: Versitech Limited
    Inventors: Yi Tsun Richard Kao, Peng Gao, Xuechen Li, Ming Liu
  • Patent number: 11021456
    Abstract: Disclosed are beta and gamma-amino isoquinoline amide compounds and substituted benzamide compounds. In particular, the invention provides compounds that affect the function of kinases in a cell and that are useful as therapeutic agents or with therapeutic agents. The compounds of the invention are useful in the treatment of a variety of diseases and conditions including eye diseases such as glaucoma, cardiovascular diseases, and diseases characterized by abnormal growth, such as cancers. The invention further provides compositions containing the beta or gamma-amino isoquinoline amide compounds or substituted benzamide compounds.
    Type: Grant
    Filed: December 30, 2019
    Date of Patent: June 1, 2021
    Assignee: Aerie Pharmaceuticals, Inc.
    Inventors: Mitchell A. deLong, Jill Marie Sturdivant, Susan M. Royalty
  • Patent number: 10947196
    Abstract: The present disclosure is directed to chemical compounds and to the use of such compounds in the treatment of diseases associated with an adrenergic receptor.
    Type: Grant
    Filed: March 26, 2020
    Date of Patent: March 16, 2021
    Assignee: CuraSen Therapeutics, Inc.
    Inventors: Anthony P. Ford, Wei Chen, David Scott Carter, Jiaxin Yu
  • Patent number: 10882840
    Abstract: Disclosed are beta and gamma-amino isoquinoline amide compounds and substituted benzamide compounds. In particular, the invention provides compounds that affect the function of kinases in a cell and that are useful as therapeutic agents or with therapeutic agents. The compounds of the invention are useful in the treatment of a variety of diseases and conditions including eye diseases such as glaucoma, cardiovascular diseases, and diseases characterized by abnormal growth, such as cancers. The invention further provides compositions containing the beta or gamma-amino isoquinoline amide compounds or substituted benzamide compounds.
    Type: Grant
    Filed: December 12, 2019
    Date of Patent: January 5, 2021
    Assignee: Aerie Pharmaceuticals, Inc.
    Inventors: Mitchell A. deLong, Jill Marie Sturdivant, Susan M. Royalty
  • Patent number: 10844004
    Abstract: This application relates to solabegron zwitterion useful for the treatment of lower urinary tract symptoms such as, for example, overactive bladder and prostate disorders. Additionally, this application relates to pharmaceutical compositions and methods of treatment utilizing the solabegron zwitterion for treating lower urinary tract symptoms. This application also relates to methods of preparing solabegron hydrochloride from the solabegron zwitterion.
    Type: Grant
    Filed: January 11, 2019
    Date of Patent: November 24, 2020
    Assignee: Velicept Therapeutics, Inc.
    Inventors: Raymond E. Stevens, Dalian Zhao, Bingidimi Itute Mobele
  • Patent number: 10806794
    Abstract: Provided herein (among other things) are protease inhibitor compounds having enhanced features, along with methods for administering such compounds. For example, the subject compounds can be administered without concomitant administration of a CYP3A4 inhibitor, have increased therapeutic index and/or increased potency, and are low-resistance inducing in nature.
    Type: Grant
    Filed: August 21, 2018
    Date of Patent: October 20, 2020
    Assignee: Nektar Therapeutics
    Inventors: C. Simone Jude-Fishburn, Laurie A. VanderVeen, Timothy A. Riley
  • Patent number: 10791738
    Abstract: The present invention can provide a composition and a method excellent in plant protection effect against diseases and pests. The composition comprises fluopyram and fluxapyroxad, and the method comprises a step of applying fluopyram and fluxapyroxad to a plant or soil for cultivating the plant.
    Type: Grant
    Filed: March 12, 2020
    Date of Patent: October 6, 2020
    Assignee: SUMITOMO CHEMICAL COMPANY, LIMITED
    Inventor: Masato Soma
  • Patent number: 10793552
    Abstract: The present invention provides compounds of the Formula (I), or a pharmaceutically acceptable salt thereof, where n and R1 are defined herein, methods of treating patients for liver disease, and processes for preparing the compounds.
    Type: Grant
    Filed: September 26, 2019
    Date of Patent: October 6, 2020
    Assignee: ELI LILLY AND COMPANY
    Inventors: David Andrew Coates, Luo Heng Qin, Yi Wei, Jingye Zhou
  • Patent number: 10759761
    Abstract: The present invention relates to a process for the preparation of compounds endowed with phosphodiesterase (PDE4) inhibitory activity having formula (I). The invention also relates to the process for the isolation by crystallization of the compound (I) and to its use for the preparation of pharmaceutical compositions for inhalation in combination with suitable carriers or vehicles. The present invention also relates to solvates and crystal forms of a compound of formula (I). The synthesized product is suitable for use in pharmaceutical applications for instance in the treatment of respiratory diseases.
    Type: Grant
    Filed: April 23, 2019
    Date of Patent: September 1, 2020
    Assignee: CHIESI FARMACEUTICI S.p.A.
    Inventors: Alessandro Falchi, Emilio Lutero, Emanuele Ferrari, Fausto Pivetti, Rocco Bussolati, Edoardo Mariani, Orsola Vecchi, Erhard Bappert, Caterina Ventrici
  • Patent number: 10689354
    Abstract: A compound, represented by the following formula or a medically acceptable salt thereof, having an effect of regulating the activity of an androgen receptor. In the formula, X represents S, O; Z represents (Ra)n-A-(CR13R14)0-1—(CR11R12)0-1; A represents aryl, heteroaryl; R1 represents alkyl, cycloalkyl, alkenyl, alkynyl, alkoxyalkyl, aryl, arylalkyl, heterocycle, heterocyclic alkyl; R2 represents hydrogen, halogen, alkyl, cycloalkyl, phenyl; R3 represents hydrogen, halogen, alkyl, cycloalkyl, alkoxyalkyl, alkenyl, alkynyl, cycloalkenyl, aryl, arylalkyl, heterocycle, heterocyclic alkyl, acyl, cycloalkylcarbonyl, benzoyl, spiroalkyl, adamantyl, silyl, R31R32NCO—; R4 and R5 represent hydrogen, halogen, alkyl, phenyl, and cycloalkyl.
    Type: Grant
    Filed: December 9, 2016
    Date of Patent: June 23, 2020
    Assignee: Teijin Pharma Limited
    Inventors: Shinnosuke Hosoda, Gen Unoki, Hidekazu Watanabe, Kosuke Sasaki, Jun Shibata, Emi Yokoyama, Kyohei Horie, Kenichiro Takagi
  • Patent number: 10675257
    Abstract: The present invention relates to a composition for use in treating a glioma or ameliorating the effects of a glioma, particularly glioblastoma, wherein said composition comprises a first active agent selected from the group consisting of a compound of formula (I), or a pharmaceutically acceptable salt thereof, (I) and a second active agent, which is temozolomide, or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: July 26, 2016
    Date of Patent: June 9, 2020
    Assignee: INFLECTIS BIOSCIENCE
    Inventors: Philippe Guedat, Pierre Miniou
  • Patent number: 10639300
    Abstract: Methods of treating and preventing conditions of a nasal or paranasal mucous membrane are described. The methods include administering a pharmaceutical composition including a nicotinic acetylcholine receptor (nAChR) agonist, such as (S)-(1-methyl-2-pyrrolidinyl)-pyridine, or a pharmaceutically acceptable salt, analog, precursor or derivative thereof. The methods can be used to treat a wide variety of conditions of the nasal or paranasal mucous membrane, such as nasal congestion and nose bleeds.
    Type: Grant
    Filed: April 12, 2017
    Date of Patent: May 5, 2020
    Inventor: Arturo Solis Herrera
  • Patent number: 10626100
    Abstract: The present invention provides a compound having the structure: wherein R1 is halogen, —NR5R6, —NR5—C(?O)—R6, —NH—C(?O)—OR7, —OR7, —NO2, —CN, —SR7, —SO2R7, —CO2R7, CF3, —SOR7, —POR7, —C(?S)R7, —C(?O)—NR5R6, —CH2—C(?O)—NR5R6, —C(?NR5)R6, —P(?O)(OR5)(OR6), —P(OR5)(OR6), —C(?S)R7, C1-5 alkyl, C2-5 alkenyl, C2-5 alkynyl, aryl, heteroaryl, or heterocyclyl, wherein R5, R6, and R7 and are each, independently, H, C1-5 alkyl, C2-5 alkenyl, C2-5 alkynyl, heteroalkyl, hydroxyalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C1-5 alkyl-aryl, or C1-5 alkyl-NH-aryl; Ar1 is phenyl or thiophene; wherein when Ar1 is phenyl, then R1 is other than —C(?O)—NR5R6, where one of R5 or R6 is phenyl or quinoline and the other of R5 or R6 is hydroxyalkyl, or where one of R5 or R6 is quinoline and the other of R5 or R6 is H; and wherein when Ar1 is phenyl, then R1 is other than —NR5—C(?O)—R6, where one of R5 is H and R6 is quinoline, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: December 21, 2017
    Date of Patent: April 21, 2020
    Assignees: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK, MEMORIAL SLOAN-KETTERING CANCER CENTER
    Inventors: Ronald Breslow, Paul Marks, Adaickapillai Mahendran, Yuanshan Yao
  • Patent number: 10624344
    Abstract: The present invention can provide a composition and a method excellent in plant protection effect against diseases and pests. The composition comprises fluopyram and fluxapyroxad, and the method comprises a step of applying fluopyram and fluxapyroxad to a plant or soil for cultivating the plant.
    Type: Grant
    Filed: June 14, 2019
    Date of Patent: April 21, 2020
    Assignee: SUMITOMO CHEMICAL COMPANY, LIMITED
    Inventor: Masato Soma
  • Patent number: 10548315
    Abstract: The present invention relates to the use of succinate dehydrogenase Inhibitors for extending shelf life and storage stability of fruits and vegetables, to a method for extending shelf life of fruits and vegetables by applying a succinate dehydrogenase inhibitor to the crops prior to the harvest of the fruits or vegetables and to a fruit or vegetable treated with a succinate dehydrogenase Inhibitor.
    Type: Grant
    Filed: February 12, 2010
    Date of Patent: February 4, 2020
    Assignee: BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Heiko Rieck, Hélène Lachaise, Gilbert Labourdette, Pete Howard Davies, Dominique Steiger, Luk De Maeyer, George Hauley Musson, IV, Lorianne Fought, Sylvain Tafforeau
  • Patent number: 10517857
    Abstract: Methods of treating and preventing conditions of a nasal or paranasal mucous membrane are described. The methods include administering a pharmaceutical composition including a nicotinic acetylcholine receptor (nAChR) agonist, such as (S)-(1-methyl-2-pyrrolidinyl)-pyridine, or a pharmaceutically acceptable salt, analog, precursor or derivative thereof. The methods can be used to treat a wide variety of conditions of the nasal or paranasal mucous membrane, such as nasal congestion and nose bleeds.
    Type: Grant
    Filed: April 12, 2017
    Date of Patent: December 31, 2019
    Inventor: Arturo Solis Herrera
  • Patent number: 10500190
    Abstract: A pharmaceutical composition for sublingual or buccal administration of melatonin and valerian is complexed with a beta cyclodextrin or another complexation agent. It is then encased in a liposome. The molecules encased in the liposome are then dehydrated and compounded into any of a number of dosage forms such as a dissolvable strip of material, a gum, lozenge, mint, tablet, or powder.
    Type: Grant
    Filed: April 19, 2019
    Date of Patent: December 10, 2019
    Inventor: Michael Farber
  • Patent number: 10390476
    Abstract: Provided are methods for reducing the occurrence of sudden death syndrome in plants, such as soybeans, using compounds of the general formula (I).
    Type: Grant
    Filed: November 23, 2011
    Date of Patent: August 27, 2019
    Assignee: Bayer CropScience LP
    Inventors: Jennifer Riggs, David Doran
  • Patent number: 10357507
    Abstract: The present invention provides a method of inhibiting renal fibrosis in a subject in need thereof.
    Type: Grant
    Filed: May 18, 2015
    Date of Patent: July 23, 2019
    Inventor: Sheau-Long Lee
  • Patent number: 10350200
    Abstract: The present invention is directed at aqueous suspensions of oxime compounds, such as 2-pyridine aldoxime methyl chloride (2-PAM Cl) for autoinjectors. The suspensions are able to provide 600 mg of 2-PAM Cl in one relatively small dose of less than or equal to 1.0 mL, and are particularly useful for placement in relatively small size autoinjectors.
    Type: Grant
    Filed: January 23, 2017
    Date of Patent: July 16, 2019
    Assignee: SOUTHWEST RESEARCH INSTITUTE
    Inventors: Hong Dixon, Joseph A. McDonough, Larry A. Cabell
  • Patent number: 10266499
    Abstract: The present invention relates to a compound of formula (I): wherein R1 is R3—IPU and R2 is the acyloxy residue of diclofenac, and specified by the following structures: wherein OH—R3—IPU is selected from and R4 and R5 may be the same or different selected from H and CH3 and salts, solvates and hydrates thereof.
    Type: Grant
    Filed: October 27, 2015
    Date of Patent: April 23, 2019
    Inventor: Claus Selch Larsen
  • Patent number: 10253027
    Abstract: The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.
    Type: Grant
    Filed: July 1, 2014
    Date of Patent: April 9, 2019
    Assignees: Bristol-Myers Squibb Company, Syngene International Limited, Bristol-Myers Squibb Company
    Inventors: Richard A. Hartz, Vijay T. Ahuja, Joanne J. Bronson, Carolyn Diane Dzierba, John E. Macor, Susheel Jethanand Nara, Ramkumar Rajamani
  • Patent number: 10253372
    Abstract: The present invention relates to the methods and products for detection of colorectal cancer. Additionally, the present invention relates to methods and products for determining the probability, risk or incidence of colorectal cancer and of colorectal cancer metastasis. The products and methods of the present invention include detecting the level of expression of COL10A1 or MMP11, in combination, from samples, including tissue samples, from humans who currently have been diagnosed with cancer or who were previously diagnosed with cancer and those who are thought to have cancer and are undergoing diagnosis.
    Type: Grant
    Filed: August 29, 2016
    Date of Patent: April 9, 2019
    Assignee: Siemens Healthcare Diagnostics Inc.
    Inventors: Michael Stürzl, Roland S. Croner, Andreas Konrad
  • Patent number: 10246448
    Abstract: The invention relates to compounds acting as antagonists of Transient Receptor Potential cation channel subfamily M member 8 (TRPM8), and having formula (I): Said compounds are useful in the treatment of diseases associated with activity of TRPM8 such as pain, ischaemia, neurodegeneration, stroke, psychiatric disorders, itch, irritable bowel diseases, cold-induced and/or exacerbated-respiratory disorders, urological disorders, corneal disorders associated to disturbances in the production of the tears and/or altered blinking such as epiphora and dry eye disease.
    Type: Grant
    Filed: December 16, 2016
    Date of Patent: April 2, 2019
    Assignee: DOMPÉ FARMACEUTICI S.P.A.
    Inventors: Andrea Aramini, Gianluca Bianchini, Samuele Lillini
  • Patent number: 10238609
    Abstract: Cyanide antidote compositions and methods of use are described herein. A cyanide antidote composition may include a sulfur analog, sulfur analog derivative, or a pharmaceutically acceptable derivative of a sulfur analog.
    Type: Grant
    Filed: November 8, 2016
    Date of Patent: March 26, 2019
    Assignee: Sam Houston State University
    Inventors: Ilona Petrikovics, Csaba Jaszberenyi